{"id":"W1975881851","doi":"10.1007/s10549-007-9583-y","title":"A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy","year":2007,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Bone health and treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bisphosphonate; Bone pain; Breast cancer; Palliative care; Regimen; Metastatic breast cancer; Progressive disease; Internal medicine; Cancer; N-terminal telopeptide; Bone disease; Surgery; Oncology; Urology; Chemotherapy; Osteoporosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008371187,0.001474334,0.002563131,0.000405699,0.0004045962,0.0007698253,0.0008111661,0.001786973,0.00643523],"category_scores_gemma":[0.001021096,0.0004717844,0.001500699,0.0003946413,0.000988992,0.0005751167,0.000308103,0.003868108,0.000852966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000744854,"about_ca_system_score_gemma":0.001293849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001401093,"about_ca_topic_score_gemma":0.003644052,"domain_scores_codex":[0.9997705,0.000113371,0.000008924862,0.00004358028,0.00001517603,0.00004853949],"domain_scores_gemma":[0.9992958,0.0001842616,0.00008708483,0.00004564379,0.00002825349,0.0003589642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9488226,0.01503122,0.001023146,0.0005376681,0.0007337045,0.0001110107,0.00008874387,0.000953123,0.009155947,0.0001768709,0.001486007,0.02187999],"study_design_scores_gemma":[0.8815909,0.1146097,0.00169232,0.00002273147,0.0002604614,0.00008316547,0.00002535221,0.0003470333,0.0004876925,0.0001074777,0.0007623888,0.0000108164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886746,0.003018731,0.0004165322,0.0009483813,0.0003408593,0.002649686,0.001309094,0.00007712209,0.002565087],"genre_scores_gemma":[0.9852253,0.00256998,0.001396947,0.00147273,0.0003666715,0.003540415,0.002274181,0.00002689172,0.003126988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00643523,"threshold_uncertainty_score":0.02152795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08039643999595886,"score_gpt":0.4560733433959697,"score_spread":0.3756769034000108,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}